ストックスクリーナーアプリを入手
749.44
0.22%
-1.69
プレマーケット:
732.16
-17.28
-2.31%
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Regeneron beats quarterly profit estimates on Dupixent strength - Yahoo! Finance Canada
Regeneron: Q4 Earnings Snapshot - kare11.com
Regeneron posts Q4 beat thanks to Sanofi tie-up (REGN:NASDAQ) - Seeking Alpha
Regeneron (REGN) Surpasses Q4 Expectations with Strong Earnings - GuruFocus
Summit Global Investments Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Projects 2026 Capital Expenditure of $1.3 Billi - GuruFocus
Regeneron (REGN) Achieves Revenue Milestone and Expands Medicine Approvals - GuruFocus
REGENERON PHARMACEUTICALS ($REGN) Releases Q4 2025 Earnings - Quiver Quantitative
Regeneron Pharmaceuticals Q4 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - The Manila Times
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA - TradingView
Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 - Nasdaq
New York State Common Retirement Fund Sells 7,500 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of New York Mellon Corp Acquires 15,006 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Is Regeneron (REGN) Offering Value After Recent Share Price Softness? - Yahoo Finance UK
TD Cowen Adjusts Regeneron Pharmaceuticals PT to $820 From $800, Maintains Buy Rating - marketscreener.com
Ruffer LLP Takes $12.11 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN) - Insider Monkey
Mirae Asset Global Investments Co. Ltd. Purchases 5,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Purchases 1,741 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Escalator: Regeneron, Lundbeck, Amgen and more - Medical Marketing and Media
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar (ALVO:NASDAQ) - Seeking Alpha
Alvotech deal clears way for new Eylea alternative in global markets - Stock Titan
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow - The Globe and Mail
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView
Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook - simplywall.st
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha
Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating - marketscreener.com
Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sovran Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st
Y Intercept Hong Kong Ltd Sells 24,556 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teacher Retirement System of Texas Sells 2,558 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st
Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Regeneron: Q4 Earnings PreviewWhy I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN) - Seeking Alpha
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines - Pharma Voice
The Truth About Regeneron Pharmaceuticals: Why Wall Street Can’t Stop Watching REGN - AD HOC NEWS
How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - Yahoo Finance
Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Weakness? - simplywall.st
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday - MarketBeat
Bi Specific Antibodies Therapy Market Is Booming Worldwide | AbbVie • Regeneron Pharmaceuticals • Pfizer - openPR.com
2 Healthcare Stocks Poised for a Comeback in 2026 - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat
REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
2 Westchester County Teens Among 40 Regeneron Science Talent Search 2026 Finalists - Patch
40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan
0.11%
0.80%
大文字化:
|
ボリューム (24 時間):